Mythos Unveiling Threatens DeFi, Strategy Dumping Undermines Faith, AI Hype Diverts Funds, Crypto Market Facing "Darkest Hour"
BlockBeats News, May 29th - This morning, Anthropic confirmed that it will soon roll out the next-generation Mythos model with super flagship intelligence to all customers in the coming weeks. Concurrently, Manuel Aráoz, founder of the well-known crypto auditing firm OpenZeppelin, publicly warned that "all DeFi, including Aave and MakerDAO, is now insecure." Mythos will become the nuclear weapon for hackers to breach encrypted DeFi.
The data is clear: After the private release of Mythos, DeFi experienced its darkest two months in history. Drift, KelpDAO, and THORChain were successively breached, leading to a complete collapse of confidence in DeFi security.
On the other hand, Strategy seems to have initiated a Bitcoin sell-off process this morning. Although the amount is not significant, this action has had a profound impact on market faith.
Furthermore, in the most crucial point, amidst the current AI investment frenzy, the evident trend of market attention and fund diversion has shown that the lack of innovation in the crypto field has exhausted practitioners' patience. The trend of investors and developers "abandoning crypto for AI" has become the norm.
In conclusion, with three major pressures compounding, the crypto industry is facing a dual test of confidence and liquidity. In the short term, DeFi TVL is under pressure, Bitcoin faith is wavering, and the trend of capital outflow may intensify, potentially leading the crypto market into a period of extreme uncertainty.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
